Diclofenac‐induced antibodies against red blood cells are heterogeneous and recognize different epitopes
- 20 July 2004
- journal article
- Published by Wiley in Transfusion
- Vol. 44 (8), 1226-1230
- https://doi.org/10.1111/j.1537-2995.2004.04025.x
Abstract
BACKGROUND: Diclofenac (DCF) is a widely used nonsteroidal anti-inflammatory drug implicated as a cause of immune hemolytic anemia. Drug derivatives have been suggested to be an important—or probably the primary—immunizing agent in drug-induced immune reactions. A systematic evaluation of 12 patients with DCF-induced immune hemolysis is reported. STUDY DESIGN AND METHODS: All sera samples were evaluated with standard serologic tests for the detection of red blood cells (RBCs) and platelet (PLT) antibodies in the presence of DCF, DCF-urine (DCF-U), and five chemically defined metabolites. RESULTS: Twelve patients’ sera samples reacted with DCF-U, but only 9 reacted with DCF. When derivatives were tested, no metabolite was recognized by all sera samples (although 4′-OH-DCF was recognized by 11/12), and no metabolite remained unrecognized. As demonstrated with Rhnull cells, the Rh complex may represent an important, but not the only, target protein for which drug-dependent antibodies are specific. PLT-reactive antibodies were not detectable. CONCLUSION: There is evidence that patients with DCF-induced immune hemolysis produce a broad spectrum of anti-DCF/RBC antibodies. 4′-OH-DCF seems to represent the most immunogenic metabolite. Nevertheless, all patients’ sera samples contain a mixture of antibodies that recognize several and distinguishable epitopes. These epitopes consist of different drug metabolites and a target protein on the RBC surface, which appears to be the Rh complex in many, but not in all, cases. Additional target proteins remain to be identified.Keywords
This publication has 14 references indexed in Scilit:
- Diclofenac-induced antibodies against RBCs and platelets: two case reports and a concise reviewTransfusion, 2003
- Immune Complex-Mediated Haemolytic Anaemia and Evans Syndrome Induced by DiclofenacVox Sanguinis, 1997
- Diclofenac‐induced immune haemolytic anaemia: simultaneous occurrence of red blood cell autoantibodies and drug‐dependent antibodiesBritish Journal of Haematology, 1996
- Sulindac‐induced immune hemolytic anemiaTransfusion, 1994
- Autoantibodies and drug-or metabolite-dependent antibodies in patients with diclofenac-induced immune haemolysisBritish Journal of Haematology, 1991
- Drug-Induced Immune Cytopenias: A Unifying Pathogenetic Concept With Special Emphasis on the Role of Drug MetabolitesTransfusion Medicine Reviews, 1990
- Immune hemolytic anemia associated with tolmetin and suprofenTransfusion, 1989
- Red cell antibodies and autoimmune haemolysis after treatment with azapropazone.BMJ, 1986
- Rhnull Red Cells and PregnancyVox Sanguinis, 1983
- Agglutinins for “Null” Red Blood CellsTransfusion, 1969